SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR® XPT HBSAGII (HBSII); HBSII IMMUNOASSAY
|
Back to Search Results |
|
Model Number N/A |
Device Problem
No Apparent Adverse Event (3189)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 01/16/2019 |
Event Type
malfunction
|
Manufacturer Narrative
|
The customer diluted the patient sample with water in 1:5 and 1:10.The 1:5 and 1:10 diluted sample results were (b)(6).The patient sample tested without dilution had a (b)(6) result.The cause for the discordant advia centaur® xpt hbsii results is unknown.Siemens healthcare diagnostics is investigating.The ifu states in the limitations section: "assay performance characteristics have not been established when the advia centaur hbsagii assay is used in conjunction with other manufacturers' assay for specific hbv serological markers.For diagnostic purposes, the advia centaur hbsagii test results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings.It is recognized that the current methods for the detection of hepatitis b surface antigen may not detect all potentially infected individuals.A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis b.A nonreactive test result in individuals with prior exposure to hepatitis b may be due to antigen levels below the detection limit of this assay or lack of antigen reactivity to the antibodies in this assay." mdr 1219913-2019-00017 (lot 142 testing) and 1219913-2019-00021 (lot 142 repeat testing) were filed for the same event.
|
|
Event Description
|
A discordant (b)(6) advia centaur xpt hbsagii (hbsii) result was obtained for a patient sample with lot 142.The result was reported to the physician and questioned.The patient presents clinical signs of (b)(6).The patient sample was tested at another site and the result was (b)(6).The first sample from the patient was repeated on alternate method 1 and the result was (b)(6).The second sample was repeated on alternate method 2 and the result was (b)(6).The patient sample was tested with the advia centaur xpt hbsagii (hbsii) lot 144 and the result was (b)(6).The patient sample was repeated with the advia centaur xpt hbsagii (hbsii) lot 142 and the result was (b)(6).Patient treatment and intervention were delayed.The customer stated hospitalization of the patient and retroviral medication supply.Currently the patient is hospitalized for treatment of (b)(6).There was no report of adverse health consequences due to the discordant hbsagii result.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2019-00020 on february 12, 2019.Siemens filed the mdr 1219913-2019-00020 supplemental report 1 on april 5, 2019.04/15/2019 additional information: the patient is currently at the end of the acute phase of the disease.Given that the patient is at the end of the acute phase of the disease obtaining more sample would not allow siemens to determine why the sample was nonreactive at the beginning of the disease.The advia centaur xpt hbsii instructions for use (ifu) (10635152 revision g, 2017-12) state in the limitations section: "it is recognized that the current methods for the detection of hepatitis b surface antigen may not detect all potentially infected individuals.A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis b.A nonreactive test result in individuals with prior exposure to hepatitis b may be due to antigen levels below the detection limit of this assay or lack of antigen reactivity to the antibodies in this assay." siemens healthcare diagnostics is awaiting further information.Mdr 1219913-2019-00017 supplemental report 2 and mdr 1219913-2019-00021 supplemental report 2 were filed for the same event.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2019-00020 on (b)(6) 2019.03/12/2019 additional information: the customer had a sample that recovered nonreactive (0.10 index) with advia centaur xpt hbsagii lots 142 and 144 but reactive with two alternate hbs methods.When the sample was diluted with water the dilutions recovered reactive with the advia centaur xpt hbsagii assay.Siemens does not recommend diluting samples in water as this will alter the sample (e.G.Protein concentration, viscosity, etc.) in such a way that the result with the diluted sample is not reliable.The sample was sent to siemens for evaluation but there was only ~200ul which was not enough to perform molecular testing and limited the testing that could be done.Siemens tested the sample with advia centaur xpt hbsagii lot 168 and the result was nonreactive.Therefore, the issue with the sample is not lot specific or specific to the customer's reagents.Siemens also diluted the sample with the low calibrator but the sample continued to recover nonreactive.If there is something in the sample interfering with the hbsagii assay, siemens was not able to dilute it out.The dilution results, which went up to 1 / 20000, do not indicate the nonreactive result was due to a high dose hook effect.According to smart remote services (srs) data at least 1400 positives samples have been tested with advia centaur xpt hbsagii lot 142 and at least 1300 positives samples have been tested with advia centaur xpt hbsagii lot 144.The sensitivity section of the advia centaur hbsii instructions for use (ifu) (10635152 revision g) lists the 95% confidence interval (ci) for sensitivity as 99.09% - 100.00%.Based on this information, the advia centaur xp hbsagii lot 142 and 144 are performing as intended since one false negative result out of 1400 positive results would mean a sensitivity of 99.9% for lot 142 and 1 false negative result out of 1300 positive results would mean a sensitivity of 99.9% for lot 144.While there is insufficient information to determine the cause of the false negative result, siemens cannot rule out typical assay performance, pre-analytical factors, or sample issue.Based on the investigation, no product problem was identified.(b)(6) 2019 additional information received for the patient: (b)(6): the patient arrives at the emergency room, with myalgia, joint pain and inflammation, so they refer him to the orthopedist.(b)(6): a joint puncture is performed, with analysis of the liquid.For that moment he presents adynamia and asthenia.Given the symptoms, they send it to the hepatologist, who decides to do the laboratory exams: 1.Pasteur: negative 2.Other laboratory: positive 3.Control: negative for hep b after the confirmation of the results, the patient is hospitalized and the management and treatment is carried out.Siemens healthcare diagnostics is awaiting further information.Mdr 1219913-2019-00017 supplemental report 1 and mdr 1219913-2019-00021 supplemental report 1 were filed for the same event.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2019-00020 on (b)(6)2019.Siemens filed the mdr 1219913-2019-00020 supplemental report 1 on(b)(6)2019.Siemens filed the mdr 1219913-2019-00020 supplemental report 2 on (b)(6)2019.(b)(6)2019 additional information: the customer had a sample that recovered nonreactive (0.10 index) with advia centaur xpt hbsagii lots 142 and 144 but reactive with the alternate hbs methods.When the sample was diluted with water, the dilutions recovered reactive with the advia centaur xpt hbsagii assay.Siemens does not recommend diluting samples in water as this will alter the sample (e.G.Protein concentration, viscosity, etc.) in such a way that the result with the diluted sample is not reliable.The sample was sent to siemens for evaluation but there was only ~200ul which was not enough to perform molecular testing and limited the testing that could be done.Siemens tested the sample with advia centaur xpt hbsagii lot 168 and the result was nonreactive.So, the issue with the sample is not lot specific or specific to the customer's reagents.The sample was also diluted with low calibrator but the sample continued to recover nonreactive.So, if there is something in the sample interfering with the assay, we were not able to dilute it out.The dilution results, which went up to 1 / 20000, do not indicate the nonreactive result was due to a high dose hook effect.According to smart remote services (srs) data at least 1400 positives samples have been tested with advia centaur xpt hbsagii lot 142 and at least 1300 positive samples have been tested with advia centaur xpt hbsagii lot 144.The sensitivity section of the advia centaur hbsii instructions for use (ifu) (10635152 revision g) lists the 95% confidence interval (ci) for sensitivity as 99.09% - 100.00%.Based on this information advia centaur xp hbsagii lot 142 and 144 are performing as intended since 1 false negative result out of 1400 positive results would mean a sensitivity of 99.9% for lot 142 and 1 false negative result out of 1300 positive results would mean a sensitivity of 99.9% for lot 144.Please note that as stated in the limitations section of the advia centaur xpt hbsii instructions for use (ifu) (10635152 revision g, 2017-12): "it is recognized that the current methods for the detection of hepatitis b surface antigen may not detect all potentially infected individuals.A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis b.A nonreactive test result in individuals with prior exposure to hepatitis b may be due to antigen levels below the detection limit of this assay or lack of antigen reactivity to the antibodies in this assay." while there is insufficient information to determine the cause of the false negative result, typical assay performance, pre-analytical factors, or sample issue cannot be ruled out.Based on the investigation, no product problem was identified.The instrument is performing within specifications.No further evaluation of the device is required.Mdr 1219913-2019-00017 supplemental report 3 and mdr 1219913-2019-00021 supplemental report 3 were filed for the same event.
|
|
Search Alerts/Recalls
|
|
|